The purpose of the study is to see how well Concizumab works in preventing bleeding episodes compared to the previous treatment the children were receiving. The study will involve children who have not used Concizumab before. Participants will receive regular injections of Concizumab over a period of time, and the number of bleeding episodes they experience will be monitored and compared to their previous treatment.

Throughout the study, researchers will also keep track of any side effects or reactions to the medication, such as injection site reactions or the development of antibodies against Concizumab. The study aims to provide valuable information on the safety and effectiveness of Concizumab in managing bleeding episodes in young children with hemophilia.

During the 24‑week period, participants are randomly assigned to one of the two groups and neither the participants nor the study staff know which treatment is given (double‑blind). Regular visits include blood tests that measure NT-proBNP, a protein that rises when the heart is under stress, and imaging tests such as an ultrasound of the heart (echocardiogram) that assess measurements like left ventricular end-diastolic volume index, left ventricular end-systolic volume index, E/e′ ratio, global longitudinal strain and left atrial volume index. Participants also complete the Kansas City cardiomyopathy questionnaire to report symptoms and quality of life, and a routine 12‑lead Electrocardiogram is performed to check the heart’s electrical activity. Throughout the study, safety is monitored by recording any side effects and checking routine laboratory values.

The treatment being studied involves a combination of two medications: MK-1084 and pembrolizumab. Pembrolizumab is also known by the brand name KEYTRUDA and is given as an infusion, which means it is delivered directly into the bloodstream through a vein. MK-1084 is taken as a tablet. Some participants in the study will receive pembrolizumab with MK-1084, while others will receive pembrolizumab with a placebo, which looks like the real medication but does not contain any active ingredients. The purpose of the study is to compare the effectiveness of these two treatment combinations.

Participants in the study will receive their assigned treatment and will be monitored over a period of time to see how their cancer responds. The study will look at how long participants live without their cancer getting worse, known as progression-free survival, and overall survival, which is the length of time participants live after starting the treatment. The study will also track any side effects experienced by participants and how the treatment affects their quality of life. This information will help researchers understand the potential benefits and risks of the new treatment combination for people with this specific type of lung cancer.

The purpose of the study is to determine whether the experimental drug can restore a normal heart rhythm, known as sinus rhythm. In the trial, adult participants are randomly assigned to receive either the study drug or the placebo. The assigned treatment is delivered by a short intravenous infusion, and participants are observed for at least three hours to see if their heart rhythm changes from the irregular pattern to a steady one without needing additional procedures. Safety checks are performed throughout the visit, and a blood sample is taken at the end of the infusion to measure how much of the medicine is present in the body.

Participants will be randomly assigned to receive either elecoglipron at one of two dose levels or the placebo, while continuing their usual insulin therapy. Over about 40 weeks, they will visit the clinic several times for simple blood tests, including a test called HbA1c that shows the average blood sugar level over the past few months. The study will also check changes in body weight and blood pressure, but no detailed procedures are described here.

The purpose of the trial is to determine whether AZD8965 can reduce the loss of lung function compared with placebo, using the change in FVC (forced vital capacity, the amount of air exhaled forcefully after a deep breath) as the main measure over about 24 weeks. Participants will be screened, then randomly assigned to receive either the study drug or placebo for a six‑month period, with regular clinic visits for safety checks, blood samples, and simple breathing tests. Throughout the study, any side effects and overall health will be closely monitored.

The main goal of the study is to see whether the new combination works better and is safe compared with the single drug. Participants will receive their assigned injection at regular visits over about one year, and they will come to the clinic for check‑ups, blood tests, and questionnaires about symptoms. The study is double‑blind, meaning neither the participants nor the doctors know which treatment is being given, to keep the results unbiased.

The key result the researchers are looking for is clinical remission at week 48, which means the person’s symptoms have cleared enough that they no longer need daily medication for the disease. Throughout the trial, safety will be monitored by checking for any side effects or changes in health.

During the trial, each person will take the assigned tablets every day for about 40 weeks. Regular visits will include simple blood tests, such as the HbA1c test, which shows the average blood‑sugar level over the past few months, measurements of body weight, and checks of blood pressure. The schedule is designed to monitor how the medicines affect blood sugar, weight, and overall health while watching for any side effects.

The study is designed to continue treatment for patients who have already participated in previous research with rocatinlimab. Participants will receive either rocatinlimab or placebo through injections under the skin. This is a long-term study that will monitor how well patients maintain improvement in their skin condition and any side effects that may occur during treatment.

The research will track various aspects of the skin condition, including changes in skin appearance, itching severity, and overall symptoms. The study will particularly focus on monitoring the safety of the treatment by recording any side effects and checking laboratory test results and vital signs throughout the treatment period.

Participants will take the study medication by mouth once a day for about two months. At the beginning and after the eight‑week period, they will complete the Oxford Depression Questionnaire (ODQ), a set of questions that measures how often different feelings are experienced. Additional questionnaires will ask about overall mood, thinking and memory (cognition), sleep quality, daily functioning at work, school, or home, and overall quality of life. The study follows a simple schedule of visits and questionnaire completion without any invasive procedures.

Participants are randomly assigned to receive either Enpatoran or placebo for a period of 24 weeks while continuing any usual care. The skin severity is measured using the CLASI score, which rates the extent and intensity of rash, and overall lupus activity is also evaluated with the BICLA assessment. Throughout the study, safety is monitored by recording any adverse events and laboratory changes. Visits occur at regular intervals to collect the necessary information and to ensure participant well‑being.

The purpose of the study is to evaluate whether Orelabrutinib can delay the worsening of disability compared with placebo. Participants will receive the assigned tablet each day for several years and will attend regular clinic visits where their ability to perform everyday tasks is checked and brain scans using MRI are performed to look for new lesions. The study will track how long it takes before a confirmed increase in disability occurs and will record any safety concerns throughout the trial.

The purpose of the study is to determine whether the drug can reduce skin thickness and be tolerated well over an extended period.

Participants will receive either the study medication or placebo by injection regularly for about one year and may continue for up to three years if they choose to stay in the extension phase. During the study, doctors will check the skin using a tool called the modified Rodnan Skin Score, which rates how tight the skin feels, and will perform a breathing test known as forced vital capacity to monitor lung function. Routine check‑ups will also include simple safety measurements such as blood tests, vital signs, and questions about any side effects.

Participants are randomly assigned to receive either the combination therapy or a single oral drug, and treatment continues until disease progression or unacceptable side effects occur. Visits include regular health checks, blood tests, and imaging scans to monitor the tumor and overall health. The study follows patients for several months to record how long they live, how long the disease stays stable, and any side effects that arise.

The purpose of the study is to find out whether the new medicine can improve breathing and reduce serious flare‑ups compared with the placebo. People who join will be randomly assigned to one of the two groups, and neither the participants nor the study staff will know which treatment each person receives (double‑blind). Over several months, participants will come to the clinic for routine visits where their lung function, symptoms and overall health will be checked.

During the study, participants will receive the injections at set intervals and will have simple breathing tests, such as measuring forced expiratory volume in one second (FEV1), which shows how much air can be exhaled quickly. They will also answer short questionnaires about how they feel, and will have basic safety checks like blood tests and a quick heart rhythm check (ECG). All of this information helps researchers see if the medicine works and is safe.

Participants will take the study tablets by mouth each day for several months and will return to the clinic for regular check‑ups, which may include imaging scans and urine tests to watch the cancer and any side effects. A “complete response” means that doctors cannot see any sign of the tumor after treatment. If the cancer was originally considered too large to be removed surgically, doctors will also see whether it becomes small enough for surgery, such as removal of part of the kidney (nephrectomy) or the entire kidney and ureter (nephroureterectomy). The study will continue until the planned treatment period ends or until a decision is made based on the participant’s health.

People in the study are assigned by chance to receive different doses of ELV001 or placebo tablets. The study is double-blind, which means that the treatment given is not known to the participants or the study team during the study. Treatment is taken for a period of time, and the health of the joints and overall condition are checked during the study visits. Safety is also watched closely, including possible side effects and changes in heart tracing, blood tests, and vital signs.

The study is looking at whether ELV001 can improve signs and symptoms of active rheumatoid arthritis when added to standard treatment. It also compares different dose levels to see how they work and how well they are tolerated.

The study is planned to last about 12 months for each person. It compares the two inhaled medicines in a random way, and the treatment is given through an inhaler. During the study, asthma symptoms and general control of asthma are checked at several visits, and the treatment is continued while these checks are done. The main purpose of the study is to see whether Trimbow works at least as well as Fostair for asthma control.

The study also looks at how often people have worse asthma attacks, how often they need steroid tablets by mouth, and whether breathing and quality of life change during the study. Safety is also watched throughout the treatment period.

People in the study are assigned by chance to receive either orelabrutinib or placebo. The study is set up so that neither the participants nor the study doctors know which treatment is being given during the trial. Treatment is taken over time, and the study follows participants to see how their condition changes during the study period.

PPMS can affect walking, balance, hand use, and other body functions. Disability progression means a gradual increase in these problems. The study is designed to compare how often this worsening happens in the two groups.

The study is a Phase 3 trial, which means it is being done in a larger group of people to better understand how well the treatment works and how safe it is. People taking part are assigned by chance to receive either nipocalimab or placebo. The treatment is given over time, and the study team follows participants through the treatment period to observe how the disease changes.

The study is carried out over short treatment periods. Participants receive NHS7108 or Zenpep by mouth, and the treatments are compared in a crossover design, which means the same person may receive more than one study treatment at different times. During the study, health checks are done to look for side effects and changes in routine medical tests, heart tracing, and physical examination findings. The study also looks at how well food is digested and at changes in stomach and bowel symptoms, including stool frequency and stool consistency.

The main focus is on different doses of NHS7108 taken daily for 14 days. The study compares these doses with Zenpep and follows changes in digestion-related measures such as nitrogen absorption, which shows how well protein from food is being taken up by the body, and fat absorption. It also checks levels of certain fats in the blood after a meal and records digestive symptoms over time.

The study follows people who have already completed an earlier asciminib study and are considered by the doctor to still benefit from treatment. Treatment is continued over time, and regular study visits are planned so that health and any side effects can be watched. The study looks at possible adverse events, which are unwanted health problems that happen during treatment, and serious adverse events, which are more severe health problems. In some parts of the study, other tyrosine kinase inhibitors that may have been used in earlier studies include nilotinib, dasatinib, imatinib, and bosutinib.

The study is designed to provide continued access to the same study treatment received before while long-term safety is followed over time.

Adults and adolescents in the study are assigned by chance to receive either GB-0895 or placebo, and neither the participants nor the study team knows which one is given during the study. Treatment is given over about 52 weeks, with regular study visits during that time. The study looks at how asthma changes over the year, including flare-ups, breathing, asthma symptoms, and daily life with asthma.

Some medical terms used in the study include exacerbations, which means asthma flare-ups that are bad enough to need steroid medicine or a hospital or emergency room visit, and forced expiratory volume in 1 second (FEV1), which is the amount of air that can be blown out in one second. The study also uses systemic corticosteroids, which are steroid medicines that work throughout the body.

The study is a long-term extension, which means it follows people over a longer period after earlier treatment. During the trial, the medicine is taken by mouth and participants are watched over time for side effects and other health changes. Regular checkups and laboratory tests are used to follow general health, joint symptoms, and skin symptoms while treatment continues.

The aim is to see if adding Panzyga can lower the chance of a major infection or death in this vulnerable group. Participants will receive the assigned infusion once every few weeks for several months, and they will be checked regularly by doctors for any signs of infection, side effects, or changes in health. The study is set up so that neither the participants nor the doctors know which infusion is being given, to keep the comparison fair.

Throughout the trial, any infection that occurs will be recorded, and an independent group of experts will decide whether it meets the definition of a major infection. Safety will also be monitored by looking at reported side effects and routine lab tests. The information gathered will help determine whether the treatment is safe and effective for preventing serious infections in people with weak immune systems due to their underlying disease and therapy.

The purpose of the study is to find out whether adding ianalumab to the usual treatment leads to a better disease response than placebo, using the SRI-4 score at week 60 as the main measure. Participants are randomly assigned to receive either the drug or placebo for about a year, with regular clinic visits for safety checks and disease assessments while they continue their regular medicines; the dose of steroids may be lowered if the disease improves.

Researchers will record how many participants show improvement in disease activity, avoid serious flare‑ups, and are able to reduce steroid use to 5 mg per day or less. They will also monitor for side effects and collect blood samples to check drug levels and any immune reaction against the drug. The study ends after the 60‑week treatment period, followed by a short follow‑up phase.

The study follows people for a long period and looks at whether normal thyroid function can be kept after treatment has been stopped. During the study, adults receive the study medicine and are then observed over time to see whether thyroid levels remain stable without ATD (anti-thyroid drugs, medicines that lower thyroid hormone). Some participants may stop the study medicine earlier or later than others as part of the study plan. The study also checks whether TRAb (thyroid-stimulating hormone receptor antibodies, proteins made by the immune system that can affect the thyroid) are no longer found in the blood.

The study is designed as a long-term extension, meaning it continues to follow people who have already taken part in earlier research with this medicine. Information is collected over many months, with the main follow-up lasting up to 52 weeks after treatment changes. The study uses groups of participants to compare how long thyroid control lasts after stopping treatment and how often the disease returns, also called a relapse.

The purpose of the study is to see how well KAI-9531 works and how safe it is. Participants are assigned by chance to receive either KAI-9531 or placebo, and neither the participants nor the study team know which treatment is being given during the study. The study continues for a long period while regular injections are given and health is followed over time.

During the study, body weight and other health measures are checked at planned visits. The study looks at changes in weight, waist size, blood pressure, blood fats such as triglycerides and cholesterol, blood sugar, and quality of life related to physical function. Safety is also monitored through medical checks, blood tests, heart tracing with ECG, and review of any side effects.

People in the study are assigned by chance to receive either KAI-9531 or placebo, and neither the participants nor the study team know which one is being given during the trial. Treatment is given over a long period, with regular study visits while the injections continue. The purpose of the study is to understand the efficacy and safety of KAI-9531 in people living with obesity or overweight and diabetes.

During the study, body weight, blood sugar, and other health measures are checked over time. The study also looks at possible side effects and at whether the body makes antibodies, which are proteins the immune system can form against a medicine. This information helps show how the treatment works and how safe it is for people taking it.

The research involves comparing the effects of the active medication against the placebo to see how it influences both positive and negative symptoms. Positive symptoms refer to behaviors that are added to a person’s experience, such as delusions, while negative symptoms involve a loss of normal functions, such as a lack of emotion or motivation. During the study, doctors will monitor various aspects of health, including physical signs, heart activity through an ECG, and changes in movement or behavior.

Participants in this trial will receive subcutaneous injection, which is a method of delivering medication into the fatty layer of the skin just below the surface. The treatment KAI-9531 or semaglutide will be administered once every week. The study is designed to observe changes in body weight and other health factors over a period of time.

Participants in the study will be assigned to receive either linaprazan glurate or lansoprazole. Because the study uses a double-dummy method to ensure that neither the researchers nor the participants know which medication is being taken, some individuals will receive combinations of the active medication and a placebo. The treatment involves taking tablets by oral use over a period of time to see how well the esophagus remains healed and to monitor any potential side effects.

Participants in the study may receive cagrilintide alone, the combination of cagrilintide and semaglutide, semaglutide alone, or a placebo. The study involves monitoring changes in Body Mass Index, which is a measurement used to determine if a person has a healthy weight for their height, and the BMI Standard Deviation Score, a calculation that compares a person’s body mass to the average for others of the same age and sex. The course of the study involves weekly injections over a period of time to observe how these substances affect body weight and overall health.

The research involves monitoring several health factors during the study period. These factors include changes in Body Mass Index, which is a way to measure body fat based on height and weight, and waist circumference. Additionally, measurements will be taken regarding systolic blood pressure and diastolic blood pressure, which represent the pressure in the arteries when the heart beats and when it rests. Other monitored aspects include blood sugar levels, such as glycated haemoglobin, and various types of lipids, which are fats found in the blood like cholesterol and triglycerides.

During the initial part of the study, participants will receive either the medication or the placebo for a period of 24 weeks. The study will monitor how the treatment affects lung function, specifically looking at the forced vital capacity, which is the total amount of air a person can exhale after taking a deep breath. Following this period, there is an option to continue in an extended phase of the study for an additional 24 weeks.

The purpose of the study is to compare the effectiveness and safety of the two treatments in reducing the need for red blood cell transfusions. Participants are randomly assigned to receive either elritercept or epoetin alfa and will be treated for up to 24 weeks. During this time, they will have regular clinic visits where blood samples are taken to check hemoglobin levels, which indicate how well the blood is carrying oxygen, and doctors will record whether transfusions are still needed.

The study involves a series of visits scheduled roughly every few weeks. At each visit, a healthcare professional will administer the injection, perform a quick blood test, and ask about any side effects. The overall goal is to see if participants can stay without transfusions for a sustained period while their hemoglobin improves.

Participants will receive the treatment through a subcutaneous injection, which means the medicine is administered into the fatty layer of tissue just under the skin, using a pre-filled pen once a week. Throughout the study, changes in body weight and levels of pain in the knee will be observed. Other factors such as physical function, waist size, and certain blood measurements like cholesterol and blood pressure may also be monitored to understand the overall impact of the treatment.

Participants in the study will receive either the test medication or a placebo. The medication is administered through a subcutaneous injection, which means it is delivered into the fatty layer of tissue just under the skin, using a pre-filled pen once per week. During the study, changes in body weight, waist size, and various health measurements will be monitored. Additionally, the impact on knee pain, stiffness, and physical movement will be observed to see how the treatment affects daily function.

The study will monitor how the body processes the medication, a process known as pharmacokinetics. It will also look at how well the drug works to reduce symptoms and whether it causes any side effects. During the course of the study, participants will be observed over several weeks to track changes in their condition and any potential reactions to the treatment.

Participants in this study will be assigned to receive either MET097 or a placebo. The study is designed to compare how much body weight changes over a specific period of time. During the course of the trial, individuals will receive their assigned treatment once every week. The process involves monitoring weight changes and other health factors over a long period, extending up to 84 weeks, to observe the impact of the medication on overall health.